Investors and traders frequently compare stocks within the same industry to assess relative value, risk profiles, and growth potential. Baxter International Inc. (BAX), Becton, Dickinson and Company (BDX), and CONMED Corporation (CNMD) are all participants in the medical technology and healthcare products space. This comparison highlights differences in business scale, recent financial results, and market positioning. Portfolio managers, sector analysts, and active traders monitoring healthcare equities may find the analysis useful for understanding competitive dynamics and sector trends in the current environment.
Baxter International Inc. (BAX) develops and manufactures a range of healthcare products, including intravenous solutions, infusion systems, parenteral nutrition therapies, and surgical hemostats. The company serves hospitals, dialysis centers, and other care settings across multiple regions. In recent weeks, BAX shares reflected mixed sentiment influenced by quarterly results that showed sales increases alongside broader market pressures on healthcare names. Performance has been shaped by factors including product demand stability and cost management initiatives, with the stock trading in a lower price range compared to larger peers.
Becton, Dickinson and Company (BDX) provides medical technology solutions spanning medication management, diagnostics, and interventional procedures. Its portfolio includes devices used in hospitals and laboratories worldwide. Recent market activity for BDX featured earnings that exceeded analyst expectations in key metrics, supporting a relatively stable share price trajectory. Influences on performance include consistent revenue contributions from core segments and ongoing operational adjustments, positioning the company as a larger-capitalization name within the sector.
CONMED Corporation (CNMD) focuses on surgical and medical devices, including equipment for arthroscopy, electrosurgery, and patient monitoring. The company serves healthcare facilities with products aimed at minimally invasive procedures. In recent weeks, CNMD shares responded positively to quarterly results that included adjusted earnings above consensus and an upward revision to full-year guidance. Performance drivers encompassed organic sales trends and operational execution, contributing to heightened trading interest relative to earlier periods.
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots from a larger collection of hundreds available on the platform. These bots trade thousands of different tickers across various strategies, timeframes, and performance profiles. Only those demonstrating strong suitability for prevailing market conditions appear in the trending section, with available statistics covering win rates, drawdowns, and trade volumes that can range widely depending on the bot’s design. All AI trading bots feature distinct trading styles, risk parameters, and ticker sets. Review the full selection on the Trending AI Robots page for additional details.
The three companies differ notably in scale and focus. Baxter International Inc. (BAX) emphasizes fluid management and generic pharmaceuticals with a broad but more fragmented product line, while Becton, Dickinson and Company (BDX) offers greater diversification across diagnostics and medication delivery at a substantially larger market capitalization. CONMED Corporation (CNMD) maintains a narrower surgical device orientation with higher sensitivity to procedure volumes. Recent momentum favored CNMD following earnings catalysts, whereas BDX showed steadier large-cap stability and BAX reflected more tempered price action. Risk factors include regulatory scrutiny common to all medical device makers, with valuation sensitivity varying by earnings visibility and debt levels. Sector exposure remains concentrated in healthcare capital equipment and supplies, where hospital capital spending and reimbursement trends influence outcomes across the group.
Based on observable factors such as earnings consistency, trend stability, and relative positioning in recent market activity, Tickeron’s AI would currently assign a higher probability of favorable near-term characteristics to Becton, Dickinson and Company (BDX). Its larger scale and diversified revenue streams provide a buffer compared with the more concentrated exposures of the other two names, though outcomes remain subject to broader sector dynamics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 1 FA rating(s) are green whileBDX’s FA Score has 2 green FA rating(s), and CNMD’s FA Score reflects 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 5 TA indicator(s) are bullish while BDX’s TA Score has 4 bullish TA indicator(s), and CNMD’s TA Score reflects 6 bullish TA indicator(s).
BAX (@Pharmaceuticals: Other) experienced а +5.31% price change this week, while BDX (@Pharmaceuticals: Other) price change was +6.79% , and CNMD (@Medical/Nursing Services) price fluctuated +6.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.34%. For the same industry, the average monthly price growth was +5.49%, and the average quarterly price growth was +2.67%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +5.84%. For the same industry, the average monthly price growth was -1.67%, and the average quarterly price growth was -9.34%.
BAX is expected to report earnings on Oct 29, 2026.
BDX is expected to report earnings on Nov 05, 2026.
CNMD is expected to report earnings on Oct 28, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+5.84% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| BAX | BDX | CNMD | |
| Capitalization | 14.2B | 48.2B | 1.47B |
| EBITDA | 762M | 4.97B | 188M |
| Gain YTD | 41.482 | 17.587 | 22.586 |
| P/E Ratio | 87.85 | 30.60 | 26.55 |
| Revenue | 11.5B | 22.2B | 1.37B |
| Total Cash | 2.15B | N/A | 37.3M |
| Total Debt | 9.67B | 17.3B | 834M |
BAX | BDX | CNMD | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 34 | 87 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 8 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 95 | 100 | |
SMR RATING 1..100 | 96 | 87 | 84 | |
PRICE GROWTH RATING 1..100 | 5 | 15 | 37 | |
P/E GROWTH RATING 1..100 | 34 | 67 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (8) in the Medical Specialties industry is in the same range as CNMD (12) and is significantly better than the same rating for BAX (93). This means that BDX's stock grew similarly to CNMD’s and significantly faster than BAX’s over the last 12 months.
BDX's Profit vs Risk Rating (95) in the Medical Specialties industry is in the same range as CNMD (100) and is in the same range as BAX (100). This means that BDX's stock grew similarly to CNMD’s and similarly to BAX’s over the last 12 months.
CNMD's SMR Rating (84) in the Medical Specialties industry is in the same range as BDX (87) and is in the same range as BAX (96). This means that CNMD's stock grew similarly to BDX’s and similarly to BAX’s over the last 12 months.
BAX's Price Growth Rating (5) in the Medical Specialties industry is in the same range as BDX (15) and is in the same range as CNMD (37). This means that BAX's stock grew similarly to BDX’s and similarly to CNMD’s over the last 12 months.
CNMD's P/E Growth Rating (12) in the Medical Specialties industry is in the same range as BAX (34) and is somewhat better than the same rating for BDX (67). This means that CNMD's stock grew similarly to BAX’s and somewhat faster than BDX’s over the last 12 months.
| BAX | BDX | CNMD | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 59% | 2 days ago 70% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 57% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 48% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 51% | 2 days ago 47% | 5 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 59% | 2 days ago 47% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 50% | 2 days ago 64% |
| Advances ODDS (%) | 5 days ago 57% | 6 days ago 44% | 12 days ago 68% |
| Declines ODDS (%) | 3 days ago 65% | 17 days ago 43% | 4 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 66% | 2 days ago 51% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 51% | 2 days ago 60% |
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +3.76% | ||
| COO - BDX | 54% Loosely correlated | -2.03% | ||
| BAX - BDX | 52% Loosely correlated | -1.17% | ||
| TMO - BDX | 50% Loosely correlated | +0.38% | ||
| CNMD - BDX | 48% Loosely correlated | +0.95% | ||
| MMSI - BDX | 45% Loosely correlated | +0.58% | ||
More | ||||
A.I.dvisor indicates that over the last year, CNMD has been loosely correlated with ENOV. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CNMD jumps, then ENOV could also see price increases.
| Ticker / NAME | Correlation To CNMD | 1D Price Change % | ||
|---|---|---|---|---|
| CNMD | 100% | +0.95% | ||
| ENOV - CNMD | 57% Loosely correlated | -12.82% | ||
| KIDS - CNMD | 54% Loosely correlated | +2.33% | ||
| IART - CNMD | 52% Loosely correlated | -3.28% | ||
| NVST - CNMD | 49% Loosely correlated | -4.37% | ||
| SYK - CNMD | 49% Loosely correlated | +0.12% | ||
More | ||||